Fabrys Disease Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Treatment, Others), By Route of Administration (Oral, Intravenous, Others) and Regional Forecast, 2024-2032

Fabry’s disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha-galactosidase enzyme leading to progressive organ dysfunction. Fabry’s disease is caused due to the abnormal accumulation of a specific fatty matter called globotriaosylceramide in multiple tissues of the body, including skin, eyes, brain, kidney, gastrointestinal system, heart, and central nervous system.

According to the U.S. National Library of Medicine, Fabry’s disease affects an estimated 1 in 40,000 to 60,000 males. Patients with Fabry’s disease suffer from severe pain of extremities, heart disorder, kidney failure, disabling gastrointestinal symptoms and stroke.

Increasing prevalence Fabry's diseases coupled with increased adoption of novel therapies such as chaperone treatment is one of the major driving factors for the growth of the global Fabry's disease treatment market. Additionally, extensive R&D activities and potential approval of promising pipeline products, including enzyme replacement therapies and substrate reduction therapies are projected to escalate the growth of the global Fabry’s disease treatment market during the forecast period.

Side effects associated with the treatment options and lack of diagnostic resources in emerging countries leading to a lower rate of diagnosis in these countries are some of the factors restraining the growth of the global Fabry's disease treatment market.

Key Players Covered

Some of the major companies that are present in the global Fabry's disease treatment market is Genzyme Corporation, Shire, Amicus Therapeutics, Inc., ISU ABXIS, JCR Pharmaceuticals Co., Ltd., Protalix, Idorsia Pharmaceuticals Ltd, AVROBIO, Inc., Biosidus S.A., Neuraltus Pharmaceuticals, Inc., and others.

SEGMENTATION 

In 2018, among treatment, enzyme replacement therapy dominated the global Fabry's disease treatment market due to the massive sales of Fabrazyme and Replagal and approvals of promising pipeline candidates. This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights

• Fabry’s Disease by Key Countries


• Advancements in Research & Development of Treatment Options


• Pipeline analysis


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

North America dominated the global Fabry's disease treatment market in 2018. Increasing adoption of novel therapies and favorable reimbursement policies are some of the factors driving the growth of the Fabry's disease treatment market in the region. Also, favorable governmental policies encouraging pharmaceutical companies to increase research and developments investments in the field of rare diseases is anticipated to drive the growth of Fabry's disease treatment market in North America.

Key Industry Developments

• In August 2018, Amicus Therapeutics, received U.S. Food and Drug Administration (FDA) approval for the Galafold (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with Fabry disease.
• In July 2018, CHIESI Farmaceutici S.p.A., received development and sales rights to the therapy in all countries outside the U.S. for PRX-102 an investigative therapy for the treatment of the Fabry’s disease from Protalix Biotherapeutics.